{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T03:48:49Z","timestamp":1793936929993,"version":"4.8.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004252","name":"Qatar University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite the availability of technological advances in traditional anti-cancer therapies, there is a need for more precise and targeted cancer treatment strategies. The wide-ranging shortfalls of conventional anticancer therapies such as systematic toxicity, compromised life quality, and limited to severe side effects are major areas of concern of conventional cancer treatment approaches. Owing to the expansion of knowledge and technological advancements in the field of cancer biology, more innovative and safe anti-cancerous approaches such as immune therapy, gene therapy and targeted therapy are rapidly evolving with the aim to address the limitations of conventional therapies. The concept of immunotherapy began with the capability of coley toxins to stimulate toll-like receptors of immune cells to provoke an immune response against cancers. With an in-depth understating of the molecular mechanisms of carcinogenesis and their relationship to disease prognosis, molecular targeted therapy approaches, that inhibit or stimulate specific cancer-promoting or cancer-inhibitory molecules respectively, have offered promising outcomes. In this review, we evaluate the achievement and challenges of these technically advanced therapies with the aim of presenting the overall progress and perspective of each approach.<\/jats:p>","DOI":"10.1007\/s11033-023-09096-8","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T10:01:52Z","timestamp":1706436112000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy"],"prefix":"10.1007","volume":"51","author":[{"given":"Aasma","family":"Zafar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Jawad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junaid","family":"Abu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,28]]},"reference":[{"key":"9096_CR1","unstructured":"Zafar A, Khan MJ, Abu J, Naeem A (2023) Progress and challenges of anti-cancerous strategies: surgery, chemotherapy, radiation and hormonal therapy. Mol Biol Report. In review"},{"issue":"1\u20133","key":"9096_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejphar.2009.09.067","volume":"625","author":"H Borghaei","year":"2009","unstructured":"Borghaei H, Smith MR, Campbell KS (2009) Immunotherapy of cancer. Eur J Pharmacol 625(1\u20133):41\u201354. https:\/\/doi.org\/10.1016\/j.ejphar.2009.09.067","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"9096_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.22270\/ajdhs.v2i4.22","volume":"2","author":"P Jain","year":"2022","unstructured":"Jain P, Darji P, Thakur BS, Jain A, Jain PK, Khare B (2022) Immunostimulants: concepts, types and functions. Asian J Dent Health Sci 2(4):26\u201334. https:\/\/doi.org\/10.22270\/ajdhs.v2i4.22","journal-title":"Asian J Dent Health Sci"},{"issue":"4","key":"9096_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.dld.2005.12.004","volume":"38","author":"A Zerbini","year":"2006","unstructured":"Zerbini A, Pilli M, Ferrari C, Missale G (2006) Is there a role for immunotherapy in hepatocellular carcinoma? Dig Liver Dis 38(4):221\u2013225. https:\/\/doi.org\/10.1016\/j.dld.2005.12.004","journal-title":"Dig Liver Dis"},{"key":"9096_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ITT.S202006","volume":"9","author":"S Guallar-Garrido","year":"2020","unstructured":"Guallar-Garrido S, Juli\u00e1n E (2020) Bacillus Calmette\u2013Gu\u00e9rin (BCG) therapy for bladder cancer: an update. ImmunoTargets Ther 9:1\u201311. https:\/\/doi.org\/10.2147\/ITT.S202006","journal-title":"ImmunoTargets Ther"},{"key":"9096_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000416543","volume":"17","author":"JE Talmadge","year":"1989","unstructured":"Talmadge JE (1989) Therapeutic properties of biological response modifiers. A discussion of preclinical and clinical studies. Contrib Gynecol Obstet 17:49\u201362","journal-title":"Contrib Gynecol Obstet"},{"issue":"4","key":"9096_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/14712598.2017.1289169","volume":"17","author":"M Sanlorenzo","year":"2017","unstructured":"Sanlorenzo M, Vujic I, Carnevale-Schianca F et al (2017) Role of interferon in melanoma: old hopes and new perspectives. Expert Opin Biol Ther 17(4):475\u2013483. https:\/\/doi.org\/10.1080\/14712598.2017.1289169","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl 1","key":"9096_CR8","first-page":"S11","volume":"6","author":"MB Atkins","year":"2000","unstructured":"Atkins MB, Kunkel L, Sznol M, Rosenberg SA (2000) High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6(Suppl 1):S11\u2013S14","journal-title":"Cancer J Sci Am"},{"issue":"11","key":"9096_CR9","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.4161\/21645515.2014.973317","volume":"10","author":"M Tagliamonte","year":"2014","unstructured":"Tagliamonte M, Petrizzo A, Tornesello ML, Buonaguro FM, Buonaguro L (2014) Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother 10(11):3332\u20133346. https:\/\/doi.org\/10.4161\/21645515.2014.973317","journal-title":"Hum Vaccin Immunother"},{"issue":"23\u201324","key":"9096_CR10","doi-asserted-by":"publisher","first-page":"1600442","DOI":"10.1002\/pmic.201600442","volume":"17","author":"E Meeusen","year":"2017","unstructured":"Meeusen E, Lim E, Mathivanan S (2017) Secreted tumor antigens\u2014immune biomarkers for diagnosis and therapy. Proteomics 17(23\u201324):1600442. https:\/\/doi.org\/10.1002\/pmic.201600442","journal-title":"Proteomics"},{"key":"9096_CR11","first-page":"6","volume":"5","author":"MM Bachinsky","year":"2005","unstructured":"Bachinsky MM, Guillen DE, Patel SR et al (2005) Mapping and binding analysis of peptides derived from the tumor-associated antigen survivin for eight HLA alleles. Cancer Immun 5:6","journal-title":"Cancer Immun"},{"issue":"32","key":"9096_CR12","doi-asserted-by":"publisher","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","volume":"26","author":"ME Dudley","year":"2008","unstructured":"Dudley ME, Yang JC, Sherry R et al (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26(32):5233\u20135239. https:\/\/doi.org\/10.1200\/JCO.2008.16.5449","journal-title":"J Clin Oncol"},{"issue":"3","key":"9096_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.smim.2010.04.007","volume":"22","author":"TW Dubensky","year":"2010","unstructured":"Dubensky TW, Reed SG (2010) Adjuvants for cancer vaccines. Semin Immunol 22(3):155\u2013161. https:\/\/doi.org\/10.1016\/j.smim.2010.04.007","journal-title":"Semin Immunol"},{"issue":"12","key":"9096_CR14","doi-asserted-by":"publisher","first-page":"6709","DOI":"10.4049\/jimmunol.0903612","volume":"184","author":"J Fourcade","year":"2010","unstructured":"Fourcade J, Sun Z, Kudela P et al (2010) Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. J Immunol 184(12):6709\u20136718. https:\/\/doi.org\/10.4049\/jimmunol.0903612","journal-title":"J Immunol"},{"issue":"8","key":"9096_CR15","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/CJI.0b013e318183af0b","volume":"31","author":"J Fourcade","year":"2008","unstructured":"Fourcade J, Kudela P, Andrade Filho PA et al (2008) Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother 31(8):781\u2013791. https:\/\/doi.org\/10.1097\/CJI.0b013e318183af0b","journal-title":"J Immunother"},{"issue":"22","key":"9096_CR16","doi-asserted-by":"publisher","first-page":"7036","DOI":"10.1158\/1078-0432.CCR-09-1544","volume":"15","author":"CL Slingluff","year":"2009","unstructured":"Slingluff CL, Petroni GR, Olson WC et al (2009) Effect of granulocyte\/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 15(22):7036\u20137044. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1544","journal-title":"Clin Cancer Res"},{"issue":"10","key":"9096_CR17","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1073\/pnas.83.10.3407","volume":"83","author":"PK Srivastava","year":"1986","unstructured":"Srivastava PK, DeLeo AB, Old LJ (1986) Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci USA 83(10):3407\u20133411. https:\/\/doi.org\/10.1073\/pnas.83.10.3407","journal-title":"Proc Natl Acad Sci USA"},{"issue":"25","key":"9096_CR18","doi-asserted-by":"publisher","first-page":"5360","DOI":"10.1016\/j.vaccine.2006.04.028","volume":"24","author":"Y Li","year":"2006","unstructured":"Li Y, Subjeck J, Yang G, Repasky E, Wang XY (2006) Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy. Vaccine 24(25):5360\u20135370. https:\/\/doi.org\/10.1016\/j.vaccine.2006.04.028","journal-title":"Vaccine"},{"issue":"9633","key":"9096_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0140-6736(08)60697-2","volume":"372","author":"C Wood","year":"2008","unstructured":"Wood C, Srivastava P, Bukowski R et al (2008) An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372(9633):145\u2013154. https:\/\/doi.org\/10.1016\/S0140-6736(08)60697-2","journal-title":"Lancet"},{"key":"9096_CR20","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.2147\/OTT.S62764","volume":"7","author":"M Shevtsov","year":"2014","unstructured":"Shevtsov M, Kim A, Samochernych A et al (2014) Pilot study of intratumoral injection of recombinant heat shock protein 70 in the treatment of malignant brain tumors in children. Onco Targets Ther 7:1071\u20131081. https:\/\/doi.org\/10.2147\/OTT.S62764","journal-title":"Onco Targets Ther"},{"issue":"8","key":"9096_CR21","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00262-015-1709-1","volume":"64","author":"Y Maeda","year":"2015","unstructured":"Maeda Y, Yoshimura K, Matsui H et al (2015) Dendritic cells transfected with heat-shock protein 70 messenger RNA for patients with hepatitis C virus-related hepatocellular carcinoma: a phase 1 dose escalation clinical trial. Cancer Immunol Immunother 64(8):1047\u20131056. https:\/\/doi.org\/10.1007\/s00262-015-1709-1","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"9096_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nm0303-269","volume":"9","author":"TA Waldmann","year":"2003","unstructured":"Waldmann TA (2003) Immunotherapy: past, present and future. Nat Med 9(3):269\u2013277. https:\/\/doi.org\/10.1038\/nm0303-269","journal-title":"Nat Med"},{"issue":"5517","key":"9096_CR23","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G K\u00f6hler","year":"1975","unstructured":"K\u00f6hler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517):495\u2013497. https:\/\/doi.org\/10.1038\/256495a0","journal-title":"Nature"},{"issue":"1","key":"9096_CR24","doi-asserted-by":"publisher","first-page":"e22789","DOI":"10.4161\/onci.22789","volume":"2","author":"E Vacchelli","year":"2013","unstructured":"Vacchelli E, Eggermont A, Galon J et al (2013) Trial watch Oncoimmunology 2(1):e22789. https:\/\/doi.org\/10.4161\/onci.22789","journal-title":"Trial watch Oncoimmunology"},{"issue":"1","key":"9096_CR25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2008.10.013","volume":"45","author":"PS Hall","year":"2009","unstructured":"Hall PS, Cameron DA (2009) Current perspective\u2014trastuzumab. Eur J Cancer 45(1):12\u201318. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.013","journal-title":"Eur J Cancer"},{"issue":"5","key":"9096_CR26","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1586\/era.12.13","volume":"12","author":"MI Braghiroli","year":"2012","unstructured":"Braghiroli MI, Sabbaga J, Hoff PM (2012) Bevacizumab: overview of the literature. Expert Rev Anticancer Ther 12(5):567\u2013580. https:\/\/doi.org\/10.1586\/era.12.13","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"9096_CR27","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3174\/ajnr.A2054","volume":"31","author":"W Bou-Assaly","year":"2010","unstructured":"Bou-Assaly W, Mukherji S (2010) Cetuximab (Erbitux). Am J Neuroradiol 31(4):626\u2013627. https:\/\/doi.org\/10.3174\/ajnr.A2054","journal-title":"Am J Neuroradiol"},{"issue":"8","key":"9096_CR28","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.2165\/11205090-000000000-00000","volume":"70","author":"GM Keating","year":"2010","unstructured":"Keating GM (2010) Panitumumab. Drugs 70(8):1059\u20131078. https:\/\/doi.org\/10.2165\/11205090-000000000-00000","journal-title":"Drugs"},{"issue":"5","key":"9096_CR29","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA et al (2022) Immune checkpoint inhibitors in cancer therapy. Curr Oncol 29(5):3044\u20133060. https:\/\/doi.org\/10.3390\/curroncol29050247","journal-title":"Curr Oncol"},{"issue":"40","key":"9096_CR30","doi-asserted-by":"publisher","first-page":"67129","DOI":"10.18632\/oncotarget.18004","volume":"8","author":"M He","year":"2017","unstructured":"He M, Chai Y, Qi J et al (2017) Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies. Oncotarget 8(40):67129\u201367139. https:\/\/doi.org\/10.18632\/oncotarget.18004","journal-title":"Oncotarget"},{"key":"9096_CR31","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K (2018) Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol 8:86. https:\/\/doi.org\/10.3389\/fonc.2018.00086","journal-title":"Front Oncol"},{"issue":"8","key":"9096_CR32","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","volume":"23","author":"S Champiat","year":"2017","unstructured":"Champiat S, Dercle L, Ammari S et al (2017) Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1. Clin Cancer Res 23(8):1920\u20131928. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1741","journal-title":"Clin Cancer Res"},{"issue":"12","key":"9096_CR33","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrclinonc.2011.160","volume":"8","author":"JP Pouget","year":"2011","unstructured":"Pouget JP, Navarro-Teulon I, Bardi\u00e8s M et al (2011) Clinical radioimmunotherapy\u2014the role of radiobiology. Nat Rev Clin Oncol 8(12):720\u2013734. https:\/\/doi.org\/10.1038\/nrclinonc.2011.160","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"9096_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1586\/14737140.5.1.39","volume":"5","author":"F Ravandi","year":"2005","unstructured":"Ravandi F, O\u2019Brien S (2005) Alemtuzumab. Expert Rev Anticancer Ther 5(1):39\u201351. https:\/\/doi.org\/10.1586\/14737140.5.1.39","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"9096_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4161\/mabs.1.2.7909","volume":"1","author":"J Descotes","year":"2009","unstructured":"Descotes J (2009) Immunotoxicity of monoclonal antibodies. MAbs 1(2):104\u2013111. https:\/\/doi.org\/10.4161\/mabs.1.2.7909","journal-title":"MAbs"},{"issue":"16","key":"9096_CR36","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/jnci\/djm086","volume":"99","author":"FA Scappaticci","year":"2007","unstructured":"Scappaticci FA, Skillings JR, Holden SN et al (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99(16):1232\u20131239. https:\/\/doi.org\/10.1093\/jnci\/djm086","journal-title":"J Natl Cancer Inst"},{"issue":"32","key":"9096_CR37","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.1200\/JCO.2008.17.8954","volume":"26","author":"L Fong","year":"2008","unstructured":"Fong L, Small EJ (2008) Anti\u2013cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26(32):5275\u20135283. https:\/\/doi.org\/10.1200\/JCO.2008.17.8954","journal-title":"J Clin Oncol"},{"issue":"3","key":"9096_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.smim.2010.03.002","volume":"22","author":"P Kalinski","year":"2010","unstructured":"Kalinski P, Okada H (2010) Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol 22(3):173\u2013182. https:\/\/doi.org\/10.1016\/j.smim.2010.03.002","journal-title":"Semin Immunol"},{"issue":"8","key":"9096_CR39","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/sj.cgt.7701064","volume":"14","author":"DM Mahvi","year":"2007","unstructured":"Mahvi DM, Henry MB, Albertini MR et al (2007) Intratumoral injection of IL-12 plasmid DNA\u2014results of a phase I\/IB clinical trial. Cancer Gene Ther 14(8):717\u2013723. https:\/\/doi.org\/10.1038\/sj.cgt.7701064","journal-title":"Cancer Gene Ther"},{"issue":"10","key":"9096_CR40","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1586\/14760584.2013.836914","volume":"12","author":"B Toussaint","year":"2013","unstructured":"Toussaint B, Chauchet X, Wang Y, Polack B, Le GA (2013) Live-attenuated bacteria as a cancer vaccine vector. Expert Rev Vaccines 12(10):1139\u20131154. https:\/\/doi.org\/10.1586\/14760584.2013.836914","journal-title":"Expert Rev Vaccines"},{"issue":"3","key":"9096_CR41","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2174\/157489212801820020","volume":"7","author":"M Turriziani","year":"2012","unstructured":"Turriziani M, Fantini M, Benvenuto M et al (2012) Carcinoembryonic antigen (CEA)-based cancer vaccines: recent patents and antitumor effects from experimental models to clinical trials. Recent Pat Anticancer Drug Discov 7(3):265\u2013296. https:\/\/doi.org\/10.2174\/157489212801820020","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"2","key":"9096_CR42","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/CJI.0b013e3181611420","volume":"31","author":"J Weber","year":"2008","unstructured":"Weber J, Boswell W, Smith J et al (2008) Phase 1 trial of intranodal injection of a Melan-A\/MART-1 DNA plasmid vaccine in patients with stage IV melanoma. J Immunother 31(2):215\u2013223. https:\/\/doi.org\/10.1097\/CJI.0b013e3181611420","journal-title":"J Immunother"},{"issue":"9","key":"9096_CR43","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1172\/JCI42672","volume":"120","author":"MA Morse","year":"2010","unstructured":"Morse MA, Hobeika AC, Osada T et al (2010) An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest 120(9):3234\u20133241. https:\/\/doi.org\/10.1172\/JCI42672","journal-title":"J Clin Invest"},{"issue":"1","key":"9096_CR44","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/nyas.14377","volume":"1499","author":"M Lopez-Yrigoyen","year":"2021","unstructured":"Lopez-Yrigoyen M, Cassetta L, Pollard JW (2021) Macrophage targeting in cancer. Ann N Y Acad Sci 1499(1):18\u201341. https:\/\/doi.org\/10.1111\/nyas.14377","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"9096_CR45","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala NJ, Leick MB, Maurer K et al (2022) Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat Med 28(9):1848\u20131859. https:\/\/doi.org\/10.1038\/s41591-022-01959-0","journal-title":"Nat Med"},{"issue":"1","key":"9096_CR46","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H, Li C, Jiang H et al (2021) A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol 14(1):161. https:\/\/doi.org\/10.1186\/s13045-021-01170-7","journal-title":"J Hematol Oncol"},{"issue":"4","key":"9096_CR47","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1200\/JCO.2005.10.206","volume":"23","author":"JL Marshall","year":"2005","unstructured":"Marshall JL, Gulley JL, Arlen PM et al (2005) Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen\u2013expressing carcinomas. J Clin Oncol 23(4):720\u2013731. https:\/\/doi.org\/10.1200\/JCO.2005.10.206","journal-title":"J Clin Oncol"},{"issue":"3","key":"9096_CR48","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3121\/cmr.4.3.218","volume":"4","author":"D Cross","year":"2006","unstructured":"Cross D, Burmester JK (2006) Gene therapy for cancer treatment: past, present and future. Clin Med Res 4(3):218\u2013227. https:\/\/doi.org\/10.3121\/cmr.4.3.218","journal-title":"Clin Med Res"},{"issue":"24","key":"9096_CR49","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1038\/sj.gt.3301353","volume":"7","author":"Y Akiyama","year":"2000","unstructured":"Akiyama Y, Watanabe M, Maruyama K, Ruscetti FW, Wiltrout RH, Yamaguchi K (2000) Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines. Gene Ther 7(24):2113\u20132121. https:\/\/doi.org\/10.1038\/sj.gt.3301353","journal-title":"Gene Ther"},{"issue":"7","key":"9096_CR50","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41416-020-0752-7","volume":"122","author":"DH Palmer","year":"2020","unstructured":"Palmer DH, Valle JW, Ma YT et al (2020) TG01\/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1\/2 trial. Br J Cancer 122(7):971\u2013977. https:\/\/doi.org\/10.1038\/s41416-020-0752-7","journal-title":"Br J Cancer"},{"issue":"6","key":"9096_CR51","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1245\/ASO.2003.07.020","volume":"10","author":"JT Mullen","year":"2003","unstructured":"Mullen JT, Tanabe KK (2003) Viral oncolysis for malignant liver tumors. Ann Surg Oncol 10(6):596\u2013605. https:\/\/doi.org\/10.1245\/ASO.2003.07.020","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"9096_CR52","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1525-0016(02)00049-7","volume":"7","author":"A Hemminki","year":"2003","unstructured":"Hemminki A, Kanerva A, Kremer EJ et al (2003) A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther 7(2):163\u2013173. https:\/\/doi.org\/10.1016\/S1525-0016(02)00049-7","journal-title":"Mol Ther"},{"issue":"14","key":"9096_CR53","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","volume":"77","author":"H Jiang","year":"2017","unstructured":"Jiang H, Rivera-Molina Y, Gomez-Manzano C et al (2017) Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res 77(14):3894\u20133907. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0468","journal-title":"Cancer Res"},{"issue":"10","key":"9096_CR54","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/gt.2011.176","volume":"19","author":"JD Dias","year":"2012","unstructured":"Dias JD, Hemminki O, Diaconu I et al (2012) Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther 19(10):988\u2013998. https:\/\/doi.org\/10.1038\/gt.2011.176","journal-title":"Gene Ther"},{"issue":"9","key":"9096_CR55","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1089\/hum.2019.059","volume":"30","author":"Y Yang","year":"2019","unstructured":"Yang Y, Xu W, Peng D et al (2019) An oncolytic adenovirus targeting transforming growth factor \u03b2 inhibits protumorigenic signals and produces immune activation: a novel approach to enhance anti-PD-1 and anti-CTLA-4 therapy. Hum Gene Ther 30(9):1117\u20131132. https:\/\/doi.org\/10.1089\/hum.2019.059","journal-title":"Hum Gene Ther"},{"issue":"17","key":"9096_CR56","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2024947","volume":"384","author":"GK Friedman","year":"2021","unstructured":"Friedman GK, Johnston JM, Bag AK et al (2021) Oncolytic HSV-1 G207 immunovirotherapy for pediatric high-grade gliomas. N Engl J Med 384(17):1613\u20131622. https:\/\/doi.org\/10.1056\/NEJMoa2024947","journal-title":"N Engl J Med"},{"issue":"9","key":"9096_CR57","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1089\/hum.2010.020","volume":"21","author":"SK Geevarghese","year":"2010","unstructured":"Geevarghese SK, Geller DA, de Haan HA et al (2010) Phase I\/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Hum Gene Ther 21(9):1119\u20131128. https:\/\/doi.org\/10.1089\/hum.2010.020","journal-title":"Hum Gene Ther"},{"issue":"4","key":"9096_CR58","doi-asserted-by":"publisher","first-page":"e001292","DOI":"10.1136\/jitc-2020-001292","volume":"9","author":"H Khalique","year":"2021","unstructured":"Khalique H, Baugh R, Dyer A et al (2021) Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy. J Immunother Cancer 9(4):e001292. https:\/\/doi.org\/10.1136\/jitc-2020-001292","journal-title":"J Immunother Cancer"},{"issue":"1","key":"9096_CR59","doi-asserted-by":"publisher","first-page":"E61","DOI":"10.1208\/aapsj070109","volume":"7","author":"SD Patil","year":"2005","unstructured":"Patil SD, Rhodes DG, Burgess DJ (2005) DNA-based therapeutics and DNA delivery systems: a comprehensive review. AAPS J 7(1):E61\u2013E77. https:\/\/doi.org\/10.1208\/aapsj070109","journal-title":"AAPS J"},{"issue":"5","key":"9096_CR60","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ymthe.2005.07.689","volume":"12","author":"JR Ohlfest","year":"2005","unstructured":"Ohlfest JR, Demorest ZL, Motooka Y et al (2005) Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol Ther 12(5):778\u2013788. https:\/\/doi.org\/10.1016\/j.ymthe.2005.07.689","journal-title":"Mol Ther"},{"issue":"1","key":"9096_CR61","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-016-0156-7","volume":"4","author":"J Kang","year":"2016","unstructured":"Kang J, Demaria S, Formenti S (2016) Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immunother Cancer 4(1):51. https:\/\/doi.org\/10.1186\/s40425-016-0156-7","journal-title":"J Immunother Cancer"},{"key":"9096_CR62","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.omto.2018.12.005","volume":"12","author":"SP Chawla","year":"2019","unstructured":"Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM (2019) A phase I-II study using Rexin-G tumor-targeted retrovector encoding a dominant-negative cyclin G1 inhibitor for advanced pancreatic cancer. Mol Ther Oncolytics 12:56\u201367. https:\/\/doi.org\/10.1016\/j.omto.2018.12.005","journal-title":"Mol Ther Oncolytics"},{"issue":"4","key":"9096_CR63","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/sj.mt.6300096","volume":"15","author":"Y Nasu","year":"2007","unstructured":"Nasu Y, Saika T, Ebara S et al (2007) Suicide gene therapy with adenoviral delivery of HSV-tK gene for patients with local recurrence of prostate cancer after hormonal therapy. Mol Ther 15(4):834\u2013840. https:\/\/doi.org\/10.1038\/sj.mt.6300096","journal-title":"Mol Ther"},{"issue":"8","key":"9096_CR64","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1158\/1078-0432.CCR-03-0388","volume":"10","author":"LL Pisters","year":"2004","unstructured":"Pisters LL, Pettaway CA, Troncoso P et al (2004) Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 10(8):2587\u20132593. https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0388","journal-title":"Clin Cancer Res"},{"issue":"5","key":"9096_CR65","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.ymthe.2004.08.002","volume":"10","author":"A Immonen","year":"2004","unstructured":"Immonen A, Vapalahti M, Tyynel\u00e4 K et al (2004) AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 10(5):967\u2013972. https:\/\/doi.org\/10.1016\/j.ymthe.2004.08.002","journal-title":"Mol Ther"},{"key":"9096_CR66","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fonc.2015.00288","volume":"5","author":"A Parrales","year":"2015","unstructured":"Parrales A, Iwakuma T (2015) Targeting oncogenic mutant p53 for cancer therapy. Front Oncol 5:288. https:\/\/doi.org\/10.3389\/fonc.2015.00288","journal-title":"Front Oncol"},{"issue":"4","key":"9096_CR67","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s11912-002-0009-z","volume":"4","author":"SG Swisher","year":"2002","unstructured":"Swisher SG, Roth JA (2002) p53 Gene therapy for lung cancer. Curr Oncol Rep 4(4):334\u2013340. https:\/\/doi.org\/10.1007\/s11912-002-0009-z","journal-title":"Curr Oncol Rep"},{"key":"9096_CR68","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.ymthe.2006.08.061","volume":"13","author":"L Li","year":"2006","unstructured":"Li L, Huang Y, Wang L, Li Y, Wen Y, Han B (2006) A combination therapy of selective intraarterial Gendicine infusion with chemotherapy for locally advanced head and neck carcinoma. Mol Ther 13:S20. https:\/\/doi.org\/10.1016\/j.ymthe.2006.08.061","journal-title":"Mol Ther"},{"issue":"2","key":"9096_CR69","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.flm.2017.06.001","volume":"1","author":"X Ke","year":"2017","unstructured":"Ke X, Shen L (2017) Molecular targeted therapy of cancer: the progress and future prospect. Front Lab Med 1(2):69\u201375. https:\/\/doi.org\/10.1016\/j.flm.2017.06.001","journal-title":"Front Lab Med"},{"issue":"31","key":"9096_CR70","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond MEH, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31):3997\u20134013. https:\/\/doi.org\/10.1200\/JCO.2013.50.9984","journal-title":"J Clin Oncol"},{"issue":"14","key":"9096_CR71","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273\u20131283. https:\/\/doi.org\/10.1056\/NEJMoa0910383","journal-title":"N Engl J Med"},{"issue":"6","key":"9096_CR72","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","volume":"2","author":"P Castel","year":"2021","unstructured":"Castel P, Toska E, Engelman JA, Scaltriti M (2021) The present and future of PI3K inhibitors for cancer therapy. Nat Cancer 2(6):587\u2013597. https:\/\/doi.org\/10.1038\/s43018-021-00218-4","journal-title":"Nat Cancer"},{"issue":"1","key":"9096_CR73","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13058-019-1154-8","volume":"21","author":"Y Xing","year":"2019","unstructured":"Xing Y, Lin NU, Maurer MA et al (2019) Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and\/or PTEN loss\/PTEN mutation. Breast Cancer Res 21(1):78. https:\/\/doi.org\/10.1186\/s13058-019-1154-8","journal-title":"Breast Cancer Res"},{"issue":"4","key":"9096_CR74","doi-asserted-by":"publisher","first-page":"15","DOI":"10.22037\/ijcn.v15i4.30591","volume":"15","author":"H Bakhtiary","year":"2021","unstructured":"Bakhtiary H, Barzegar M, Shiva S, Poorshiri B, Hajalioghli P, Herizchi GH (2021) The effect of everolimus on subependymal giant cell astrocytoma (SEGA) in children with tuberous sclerosis complex. Iran J Child Neurol 15(4):15\u201325. https:\/\/doi.org\/10.22037\/ijcn.v15i4.30591","journal-title":"Iran J Child Neurol"},{"issue":"4","key":"9096_CR75","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3747\/co.26.5137","volume":"26","author":"DG Bebb","year":"2019","unstructured":"Bebb DG, Agulnik J, Albadine R et al (2019) Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective. Curr Oncol 26(4):551\u2013557. https:\/\/doi.org\/10.3747\/co.26.5137","journal-title":"Curr Oncol"},{"issue":"12","key":"9096_CR76","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1007\/s40262-022-01167-6","volume":"61","author":"MAC Bruin","year":"2022","unstructured":"Bruin MAC, Sonke GS, Beijnen JH, Huitema ADR (2022) Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology. Clin Pharmacokinet 61(12):1649\u20131675. https:\/\/doi.org\/10.1007\/s40262-022-01167-6","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"9096_CR77","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/1541-7786.MCR-21-0277","volume":"20","author":"A Naeem","year":"2022","unstructured":"Naeem A, Harish V, Coste S et al (2022) Regulation of chemosensitivity in human medulloblastoma cells by p53 and the PI3 kinase signaling pathway. Mol Cancer Res 20(1):114\u2013126. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0277","journal-title":"Mol Cancer Res"},{"issue":"10","key":"9096_CR78","doi-asserted-by":"publisher","first-page":"854","DOI":"10.18632\/aging.100831","volume":"7","author":"S Waye","year":"2015","unstructured":"Waye S, Naeem A, Choudhry MU et al (2015) The p53 tumor suppressor protein protects against chemotherapeutic stress and apoptosis in human medulloblastoma cells. Aging (Albany NY) 7(10):854\u2013867. https:\/\/doi.org\/10.18632\/aging.100831","journal-title":"Aging (Albany NY)"},{"key":"9096_CR79","doi-asserted-by":"publisher","first-page":"109785","DOI":"10.1016\/j.intimp.2023.109785","volume":"116","author":"A Naeem","year":"2023","unstructured":"Naeem A, Knoer G, Laura Avantaggiati M, Rodriguez O, Albanese C (2023) Provocative non-canonical roles of p53 and AKT signaling: a role for thymosin \u03b24 in medulloblastoma. Int Immunopharmacol 116:109785. https:\/\/doi.org\/10.1016\/j.intimp.2023.109785","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"9096_CR80","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-018-0608-2","volume":"11","author":"GF Perini","year":"2018","unstructured":"Perini GF, Ribeiro GN, Pinto Neto JV, Campos LT, Hamerschlak N (2018) BCL-2 as therapeutic target for hematological malignancies. J Hematol Oncol 11(1):65. https:\/\/doi.org\/10.1186\/s13045-018-0608-2","journal-title":"J Hematol Oncol"},{"issue":"7","key":"9096_CR81","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1158\/0008-5472.CAN-07-5031","volume":"68","author":"CL Hann","year":"2008","unstructured":"Hann CL, Daniel VC, Sugar EA et al (2008) Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 68(7):2321\u20132328. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-5031","journal-title":"Cancer Res"},{"issue":"10","key":"9096_CR82","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.3109\/10428194.2015.1030638","volume":"56","author":"TJ Kipps","year":"2015","unstructured":"Kipps TJ, Eradat H, Grosicki S et al (2015) A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma 56(10):2826\u20132833. https:\/\/doi.org\/10.3109\/10428194.2015.1030638","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"9096_CR83","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","volume":"34","author":"M Konopleva","year":"2020","unstructured":"Konopleva M, Martinelli G, Daver N et al (2020) MDM2 inhibition: an important step forward in cancer therapy. Leukemia 34(11):2858\u20132874. https:\/\/doi.org\/10.1038\/s41375-020-0949-z","journal-title":"Leukemia"},{"issue":"8","key":"9096_CR84","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1634\/theoncologist.2009-0317","volume":"15","author":"F Kazazi-Hyseni","year":"2010","unstructured":"Kazazi-Hyseni F, Beijnen JH, Schellens JHM (2010) Bevacizumab. Oncologist 15(8):819\u2013825. https:\/\/doi.org\/10.1634\/theoncologist.2009-0317","journal-title":"Oncologist"},{"issue":"26","key":"9096_CR85","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484\u20132496. https:\/\/doi.org\/10.1056\/NEJMoa1103799","journal-title":"N Engl J Med"},{"issue":"20","key":"9096_CR86","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","volume":"377","author":"W Wick","year":"2017","unstructured":"Wick W, Gorlia T, Bendszus M et al (2017) Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med 377(20):1954\u20131963. https:\/\/doi.org\/10.1056\/NEJMoa1707358","journal-title":"N Engl J Med"},{"key":"9096_CR87","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.2147\/OTT.S61132","volume":"7","author":"G Aprile","year":"2014","unstructured":"Aprile G, Fontanella C, Rihawi K, Grossi F, Rijavec E (2014) Ramucirumab: preclinical research and clinical development. Onco Targets Ther 7:1997\u20132006. https:\/\/doi.org\/10.2147\/OTT.S61132","journal-title":"Onco Targets Ther"},{"issue":"24","key":"9096_CR88","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1200\/JCO.2006.05.8073","volume":"24","author":"A Bezjak","year":"2006","unstructured":"Bezjak A, Tu D, Seymour L et al (2006) Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada clinical trials group study BR.21. J Clin Oncol 24(24):3831\u20133837. https:\/\/doi.org\/10.1200\/JCO.2006.05.8073","journal-title":"J Clin Oncol"},{"issue":"20","key":"9096_CR89","doi-asserted-by":"publisher","first-page":"18162","DOI":"10.18632\/oncotarget.4216","volume":"6","author":"JP Wang","year":"2015","unstructured":"Wang JP, Wu CY, Yeh YC et al (2015) Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget 6(20):18162\u201318173. https:\/\/doi.org\/10.18632\/oncotarget.4216","journal-title":"Oncotarget"},{"issue":"3","key":"9096_CR90","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/annonc\/mdv597","volume":"27","author":"M Schuler","year":"2016","unstructured":"Schuler M, Yang JCH, Park K et al (2016) Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib\/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. Ann Oncol 27(3):417\u2013423. https:\/\/doi.org\/10.1093\/annonc\/mdv597","journal-title":"Ann Oncol"},{"issue":"20","key":"9096_CR91","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357(20):2040\u20132048. https:\/\/doi.org\/10.1056\/NEJMoa071834","journal-title":"N Engl J Med"},{"issue":"3","key":"9096_CR92","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","volume":"81","author":"CL Braal","year":"2021","unstructured":"Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A (2021) Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs 81(3):317\u2013331. https:\/\/doi.org\/10.1007\/s40265-020-01461-2","journal-title":"Drugs"},{"issue":"20","key":"9096_CR93","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1607303","journal-title":"N Engl J Med"},{"key":"9096_CR94","doi-asserted-by":"publisher","first-page":"737951","DOI":"10.3389\/fmed.2021.737951","volume":"8","author":"X Meng","year":"2021","unstructured":"Meng X, Gao JZ, Gomendoza SMT, Li JW, Yang S (2021) Recent advances of WEE1 inhibitors and statins in cancers with p53 mutations. Front Med 8:737951. https:\/\/doi.org\/10.3389\/fmed.2021.737951","journal-title":"Front Med"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-09096-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-023-09096-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-09096-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T15:34:17Z","timestamp":1738683257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-023-09096-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,28]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9096"],"URL":"https:\/\/doi.org\/10.1007\/s11033-023-09096-8","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,28]]},"assertion":[{"value":"18 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"219"}}